title: The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.
abstract: BACKGROUND
  Urotensin II is a vasoactive polypeptide. It is known that some vasoactive polypeptides are produced and secreted by tumor cells, and act as a paracrine growth stimulant. The aim of this study was to examine the relationship between urotensin II and its receptor's messenger RNA expression in breast cancer.
  
  
  METHODS
  Fifty-nine women with breast cancer were included in this study. The median age was 48 years. The relationships between urotensin II and urotensin II receptor mRNA expressions, which were derived from fresh breast cancer tissues and adjacent normal breast tissues, and clinical and pathological parameters, were assessed.
  
  
  RESULTS
  We found expressions of urotensin II mRNA and its receptor in 55 of 59 breast cancer tissues and in 55 of 59 normal breast tissues. We found a positive significant correlation between urotensin II and its receptor (p=0.001, r=0.632), and found a negative, but insignificant, correlation between urotensin II and age (p=0.038, r=-0.281). Urotensin II levels were higher in the premenopausal group compared to the postmenopausal group (p<0.05). The mean urotensin II receptor expression was higher in the premenopausal group (p<0.05) compared to the postmenopausal group, and its expression was also higher in the group without extra-nodal invasion compared to that of the group with extra-nodal invasion (p=0.001). Urotensin II levels were higher in the group without lymphatic invasion compared to the group with lymphatic invasion (p=0.048).
  
  
  CONCLUSIONS
  This study is the first in the English medical literature to determine the urotensin II and its receptor mRNA expressions in breast cancer tissues. Consequently, urotensin II seems be associated with menopausal status, and extra-nodal and lymphatic invasion.
authors.affiliation: Department of Internal Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaraş, Turkey.
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.affiliation: Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
authors.forename: Mehmet Emin
authors.initials: ME
authors.lastname: Kalender
authors.affiliation: Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep , Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Suner
authors.affiliation: Department of Physiology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
authors.forename: Beyhan
authors.initials: B
authors.lastname: Cengiz
authors.affiliation: Department of Medical Biology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
authors.forename: Serdar
authors.initials: S
authors.lastname: Oztuzcu
authors.affiliation: Department of Medical Biology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
authors.forename: Recep
authors.initials: R
authors.lastname: Bayraktar
authors.affiliation: Department of General Surgery, Gaziantep University, School of Medicine, Gaziantep, Turkey.
authors.forename: Ersin
authors.initials: E
authors.lastname: Borazan
authors.affiliation: Department of Medical Oncology, Hacettepe University, School of Medicine, Ankara, Turkey.
authors.forename: Taner
authors.initials: T
authors.lastname: Babacan
authors.affiliation: Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
authors.forename: Celaletdin
authors.initials: C
authors.lastname: Camci
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000378:metabolism; D017697:Premenopause / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism*; D018709:Statistics, Nonparametric; D014579:Urotensins / Q000378:metabolism*
chemical_list: D012333:RNA, Messenger; D043562:Receptors, G-Protein-Coupled; C121697:UTS2R protein, human; D014579:Urotensins; C029677:urotensin II
references.citation: Clin Cancer Res. 1998 Sep;4(9):2047-52
references.pmid: 9748118
references.citation: Circulation. 2004 Mar 16;109(10):1212-4
references.pmid: 15007012
references.citation: Peptides. 2008 May;29(5):873-80
references.pmid: 17686550
references.citation: Oncol Rep. 2010 Nov;24(5):1179-84
references.pmid: 20878108
references.citation: PLoS One. 2011 Apr 29;6(4):e19327
references.pmid: 21559414
references.citation: Ann N Y Acad Sci. 2006 Aug;1073:284-9
references.pmid: 17102097
references.citation: Biochem Biophys Res Commun. 1999 Dec 9;266(1):174-8
references.pmid: 10581185
references.citation: Clin Sci (Lond). 2002 Aug;103 Suppl 48:35S-38S
references.pmid: 12193050
references.citation: Circ Res. 2001 Jun 8;88(11):1102-4
references.pmid: 11397774
references.citation: Gen Pharmacol. 2000 Nov;35(5):227-31
references.pmid: 11888677
references.citation: Eur J Clin Invest. 2014;44(3):285-94
references.pmid: 24372535
references.citation: J Histochem Cytochem. 2002 Jul;50(7):885-9
references.pmid: 12070267
references.citation: Eur J Pharmacol. 2012 Apr 5;680(1-3):88-94
references.pmid: 22329895
references.citation: Mol Cell Endocrinol. 2008 May 14;286(1-2):251-61
references.pmid: 18308465
references.citation: J Hypertens. 2004 May;22(5):983-8
references.pmid: 15097239
references.citation: Circulation. 2002 Dec 3;106(23):2877-80
references.pmid: 12460864
references.citation: J Child Neurol. 2008 Nov;23(11):1249-53
references.pmid: 18984832
references.citation: Proc Natl Acad Sci U S A. 1980 Aug;77(8):5021-4
references.pmid: 6107911
references.citation: J Cell Biochem. 2011 Jan;112(1):341-53
references.pmid: 21080343
references.citation: Circ J. 2012;76(5):1267-73
references.pmid: 22382381
references.citation: Peptides. 2003 Feb;24(2):301-6
references.pmid: 12668216
references.citation: Pharmacol Rev. 2007 Jun;59(2):185-205
references.pmid: 17540906
references.citation: J Pharmacol Exp Ther. 2004 Oct;311(1):204-12
references.pmid: 15146030
references.citation: Ann Oncol. 2007 Sep;18 Suppl 8:viii3-7
references.pmid: 17890212
references.citation: Mol Pharmacol. 2009 Dec;76(6):1186-95
references.pmid: 19755521
references.citation: Peptides. 2001 Jul;22(7):1175-9
references.pmid: 11445248
references.citation: Cancer Res. 1989 Dec 15;49(24 Pt 1):7002-9
references.pmid: 2555057
references.citation: Am J Physiol Regul Integr Comp Physiol. 2010 May;298(5):R1156-72
references.pmid: 20421634
references.citation: Am J Hypertens. 2006 May;19(5):505-10
references.pmid: 16647624